>Go!
NEWS SEARCH

06.07.2017 | Investors

Allergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's Leading Plastic Surgery Portfolio

- Funnel Provides Novel, No-Touch Breast Implant Insertion Device for Plastic Surgeons -
- Enhances Allergan's World-Class Plastic Surgery and Regenerative Medicine Business -

DUBLIN, June 7, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan's wholly-owned subsidiary, Allergan Sales LLC agreed to acquire Keller Medical, Inc., a privately held medical device company and developer of the Keller Funnel®.  The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during breast augmentation or reconstruction procedures. Keller Medical launched the original Keller Funnel® in 2009 and the Keller Funnel® 2 in 2014, and hundreds of thousands of funnels have been used in breast augmentation or reconstruction procedures to date globally.

Allergan plc logo

"Allergan is focused on providing technologies and products to help our surgeon customers improve procedures and Keller Funnel is that product for breast augmentation and reconstruction procedures," said David Moatazedi, Senior Vice President of Medical Aesthetics at Allergan. "The Keller Funnel was developed and designed by pioneering surgeons to improve breast implantation. This is a natural complement to our world-class plastic surgery and regenerative medicine business, and marketing this innovative device further enhances our commitment to our customers and patients."

The Keller Funnel is used to assist plastic surgeons in breast augmentation and reconstruction procedures by guiding silicone gel implants into the surgical pocket. The Funnel also allows surgeons to use a "no-touch" technique, which may help minimize the introduction of bacteria and foreign material into the surgical pocket. 

"The purchase of Keller Medical demonstrates Allergan's ongoing commitment to excellence in breast augmentation and reconstruction surgery," said Louis P. Bucky, MD, Clinical Professor of Surgery, Division of Plastic Surgery at the University of Pennsylvania School of Medicine and Chief of Plastic Surgery at Pennsylvania Hospital.  "The Keller Funnel has become an innovative component to deliver the highest level of care for my cosmetic and reconstructive breast implant patients."

About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:
Investors:
Daphne Karydas
(862) 261-8006

Media:
Mark Marmur
(862) 261-7558

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-to-acquire-keller-medical-inc-adding-keller-funnel-to-companys-leading-plastic-surgery-portfolio-300470053.html

SOURCE Allergan plc

Media Contacts
Mark Marmur
Global Corporate Media Relations
+1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
+1 (201) 427-8762
Janet Kettels
International Product Media Relations
+44 773 850 6476

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488